Pierre Bigot1, Jean-Christophe Bernhard2, Vincent Flamand3, Inderbir Gill4, Grégory Verhoest5, Jean Baptiste Beauval6, François Xavier Nouhaud7, Evren Suer8, Guillaume Ploussard9, Jean François Hetet10, Jérôme Rigaud11, Eduard Baco12, Stéphane Larré13, Philippe Sebe14, Nicolas Koutlidis15, Aurélien Descazeaud16, Masatoshi Eto17, Arnaud Doerfler18, Morgan Roupret19, Nam Son Vuong20, Boris Reix21, Toru Matsugasumi4, Adnan El Bakri22, Laurence Albiges23, Michel Soulié24, Jean-Jacques Patard25, Arnaud Méjean26, Karim Bensalah27. 1. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Angers University Hospital, Angers, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. Electronic address: pibigot@chu-angers.fr. 2. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Bordeaux University Hospital, Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 3. French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Lille University Hospital, Lille, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 4. USC Institute of Urology, University of Southern California, Los Angeles, CA; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 5. Department of Urology, Pontchaillou University Hospital, Rennes, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 6. French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Toulouse University Hospital, Toulouse, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 7. French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Rouen University Hospital, Rouen, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 8. Department of Urology, University Hospital of Ankara, Ankara, Turkey; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 9. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Saint-Louis University Hospital, APHP, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 10. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Clinique Jules Vernes, Nantes, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 11. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Nantes University Hospital, Nantes, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 12. Department of Urology, University Hospital of Oslo, Oslo, Norway; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 13. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Reims University Hospital, Reims, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 14. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, Groupe hospitalier Diaconesses, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 15. Department of Urology, Dijon University Hospital, Dijon, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 16. French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Limoges University Hospital, Limoges, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 17. Department of Urology, University Hospital of Kumamoto, Kumamoto, Japan; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 18. Department of Urology, Caen University Hospital, Caen, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 19. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Department of Urology, La Pitié Salpetrière, APHP, Paris, France; Faculty of Medicine Pierre and Marie Curie, University Paris 6, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 20. Department of Urology, Bordeaux University Hospital, Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 21. Department of Urology, Lille University Hospital, Lille, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 22. Department of Urology, Groupe hospitalier Diaconesses, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 23. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; Medical Oncology Department, University Paris 11, Villejuif, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 24. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Toulouse University Hospital, Toulouse, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 25. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Medical Oncology Department, University Paris 11, Villejuif, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 26. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, HEGP, APHP, Paris, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France. 27. Cancerology Committee of the French Association of Urology (CCAFU), Paris, France; French Network for Research on Kidney Cancer (UroCCR), Bordeaux, France; Department of Urology, Bicêtre University Hospital, Le Kremlin Bicêtre, France.
Abstract
OBJECTIVE: To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). MATERIAL AND METHODS: We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed. RESULTS: We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. CONCLUSION: Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
OBJECTIVE: To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). MATERIAL AND METHODS: We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed. RESULTS: We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. CONCLUSION: Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
Authors: Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: Michael D Gillett; John C Cheville; R Jeffrey Karnes; Christine M Lohse; Eugene D Kwon; Bradley C Leibovich; Horst Zincke; Michael L Blute Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2015-01-21 Impact factor: 20.096
Authors: Maxime Crépel; Hendrik Isbarn; Umberto Capitanio; Daniel Liberman; Claudio Jeldres; Maxine Sun; Shahrokh F Shariat; Hugues Widmer; Philippe Arjane; Markus Graefen; Francesco Montorsi; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2009-07-22 Impact factor: 2.649